AtriCure designs and sells surgical devices used by cardiac surgeons and electrophysiologists to treat atrial fibrillation, manage the left atrial appendage, and reduce post-operative pain. Its portfolio is centered on open and minimally invasive ablation systems, appendage management devices such as AtriClip, and cryo nerve block products for pain management. The company’s business model combines direct sales in the U.S. and key European markets with distributor coverage in other international regions. AtriCure differentiates itself through FDA-cleared and FDA-approved technologies for persistent and long-standing persistent Afib, including hybrid therapy approaches that combine epicardial and endocardial treatment. Growth is driven by physician adoption, clinical education, new product launches, and expansion of its installed clinical footprint across cardiac surgery centers.
0,5 %
75,0 %
−2,1 %
+14,9 %
3.96
2.99
| % | |
|---|---|
| Open ablation | 30% Surgical ablation devices used in open-heart procedures to treat atrial fibrillation and related arrhythmias. |
| Minimally invasive ablation | 12% Epicardial ablation products used in less invasive procedures, including Hybrid AF Therapy. |
| Appendage management | 38% Left atrial appendage exclusion and closure devices used to reduce stroke risk in Afib patients. |
| Pain management | 20% Cryo nerve block products used to manage post-operative pain in thoracic and cardiac surgery. |
AtriCure sells primarily to hospitals and surgical centers that perform cardiac surgery, thoracic surgery, and Afib...
Hospitals performing open and minimally invasive cardiac surgery that buy ablation and appendage management devices to treat Afib and related conditions.
Centers using Hybrid AF Therapy and related tools for persistent and long-standing persistent Afib patients.
Surgical teams that use cryo nerve block products to reduce post-operative pain and improve recovery.
Distributors and direct sales customers in Europe, Canada, Australia, Asia and South America that extend market reach outside the U.S.
AtriCure generates most of its business in the United States, where it has a large direct sales force and where...
AtriCure’s strategy is to deepen physician adoption of its core franchises by investing in clinical education, sales...
Higher physician utilization drives recurring procedure demand and strengthens the company’s position in cardiac surgery workflows.
FDA clearances and supportive clinical data are central to differentiation and reimbursement acceptance.
International growth diversifies revenue and increases the addressable market beyond the U.S.
AtriCure faces commercial risk if physicians do not adopt its products broadly enough or if competing technologies gain...
The company operates in a fast-moving device market where competitors can launch alternative ablation, appendage management, or pain solutions that reduce share or pricing power.
Procedure adoption depends on Medicare and private payer coding, coverage, and payment policies, especially in the U.S.
Delays or shortages could prevent timely product delivery, require redesigns, or force FDA re-submissions.
The business relies on physician education and key opinion leaders to drive adoption and clinical training.
Management disclosed lower minimally invasive ablation sales as physicians adopt PFA catheters for some patients.
LMAT · Surgical & Medical Instruments & Apparatus
VTAK · Surgical & Medical Instruments & Apparatus
ADGM · Surgical & Medical Instruments & Apparatus
NVCR · Surgical & Medical Instruments & Apparatus
NovoCure Ltd develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment delivered through portable medical devices and arrays worn by patients.
PLSE · Surgical & Medical Instruments & Apparatus
Pulse Biosciences is a U.S.-based medical technology company focused on developing and commercializing nonthermal pulsed field ablation systems.
SYK · Surgical & Medical Instruments & Apparatus
: 11/08/2026